Formed by Cormorant Asset Management, Helix II intends to focus on the healthcare industry.
No warrants are included in the offering.
Cormorant has “indicated the interest” of buying 2.5 million shares as well as potentially investing $35 million in a private placement that would occur with the closing of a merger with the SPAC. There are no formal agreements in place for these possible investments. Cormorant is a life sciences-focused investment firm with over $2 billion AUM.
The SPAC intends to apply for a listing on the nasdaq under the symbol HLXB.
Leerink Partners is sole bookrunning manager for the offering. Read more.